Table 1 |
||||||||
|
MMP2 genotypes vs clinical, pathological and epidemiological variables |
||||||||
| Variables |
MMP2 |
|||||||
|
|
||||||||
| -1306 C/T |
p-value* |
-735 C/T |
p-value* |
|||||
|
|
|
|||||||
| CC |
CT |
TT |
CC |
CT |
TT |
|||
|
|
||||||||
| Stage at Diagnosis |
||||||||
| 0 |
34 (59%) |
19 (33%) |
5 (9%) |
48 (83%) |
10 (17%) |
0 (0%) |
||
| I |
320 (64%) |
159 (32%) |
23 (5%) |
365 (73%) |
123 (25%) |
13 (3%) |
||
| II |
152 (65%) |
72 (31%) |
9 (4%) |
184 (78%) |
49 (21%) |
2 (1%) |
||
| III |
105 (63%) |
54 (32%) |
9 (5%) |
131 (79%) |
32 (19%) |
3 (2%) |
||
| IV |
6 (67%) |
3 (33%) |
0 (0%) |
0.92 |
4 (44%) |
5 (56%) |
0 (0%) |
0.08 |
| Primary Clark Level |
||||||||
| I |
34 (59%) |
19 (33%) |
5 (9%) |
48 (83%) |
10 (17%) |
0 (0%) |
||
| II |
70 (65%) |
36 (33%) |
2 (2%) |
79 (74%) |
23 (22%) |
5 (5%) |
||
| III |
89 (60%) |
48 (32%) |
12 (8%) |
115 (77%) |
32 (21%) |
3 (2%) |
||
| IV |
308 (64%) |
155 (32%) |
22 (5%) |
358 (74%) |
116 (24%) |
10 (2%) |
||
| V |
51 (74%) |
14 (20%) |
4 (6%) |
0.20 |
54 (78%) |
15 (22%) |
0 (0%) |
0.44 |
| Thickness (mm) |
||||||||
| In situ |
34 (59%) |
19 (33%) |
5 (9%) |
48 (83%) |
10 (17%) |
0 (0%) |
||
| < 1.01 |
201 (63%) |
107 (33%) |
12 (4%) |
237 (74%) |
72 (23%) |
10 (3%) |
||
| 1.01 – 2.00 |
174 (64%) |
81 (30%) |
15 (6%) |
199 (73%) |
68 (25%) |
4 (2%) |
||
| 2.01 – 4.00 |
100 (63%) |
50 (31%) |
10 (6%) |
124 (78%) |
33 (21%) |
2 (1%) |
||
| > 4.00 |
81 (68%) |
35 (29%) |
4 (3%) |
0.72 |
94 (78%) |
25 (21%) |
1 (1%) |
0.44 |
| TILs |
||||||||
| Absent |
129 (63%) |
67 (33%) |
9 (4%) |
161 (79%) |
40 (20%) |
3 (2%) |
||
| Non-brisk |
262 (67%) |
111 (28%) |
21 (5%) |
289 (73%) |
95 (24%) |
10 (3%) |
||
| Brisk |
19 (63%) |
9 (30%) |
2 (7%) |
0.80 |
21 (68%) |
10 (32%) |
0 (0%) |
0.32 |
| Distant Metastasis |
||||||||
| Yes |
86 (67%) |
39 (30%) |
4 (3%) |
97 (76%) |
29 (23%) |
2 (2%) |
||
| No |
543 (63%) |
281 (32%) |
42 (5%) |
0.28 |
653 (75%) |
196 (23%) |
17 (2%) |
0.88 |
| Intransit Metastasis |
||||||||
| No |
590 (63%) |
302 (32%) |
46 (5%) |
705 (75%) |
216 (23%) |
16 (2%) |
||
| Yes |
18 (67%) |
9 (33%) |
0 (0%) |
0.44 |
22 (82%) |
3 (11%) |
2 (7%) |
0.96 |
| Number of Moles |
||||||||
| None |
161 (62%) |
84 (33%) |
13 (5%) |
201 (77%) |
54 (21%) |
5 (2%) |
||
| Few |
311 (63%) |
166 (33%) |
20 (4%) |
380 (77%) |
105 (21%) |
11 (2%) |
||
| Moderate |
112 (67%) |
51 (30%) |
5 (3%) |
115 (69%) |
49 (30%) |
2 (1%) |
||
| Many |
22 (55%) |
11 (28%) |
7 (18%) |
< 0.01 |
29 (73%) |
10 (25%) |
1 (3%) |
0.40 |
| Phenotypic Index |
||||||||
| 1 (low risk) |
26 (68%) |
11 (29%) |
1 (3%) |
31 (82%) |
6 (16%) |
1 (3%) |
||
| 2 |
132 (63%) |
66 (32%) |
11 (5%) |
156 (75%) |
47 (23%) |
4 (2%) |
||
| 3 |
206 (65%) |
93 (29%) |
18 (6%) |
231 (73%) |
76 (24%) |
10 (3%) |
||
| 4 |
191 (59%) |
122 (38%) |
11 (3%) |
254 (78%) |
68 (21%) |
4 (1%) |
||
| 5 (high risk) |
73 (70%) |
27 (26%) |
5 (5%) |
0.28 |
76 (73%) |
28 (27%) |
0 (0%) |
0.36 |
|
* The associations were examined in three different ways (see statistical methods for a detailed explanation). The p-values shown refer to the analysis of the three individual genotypes, and appear in bold font if ≤ 0.05. The significance was lost after adjustment for age, sex, phenotypic index, moles, freckles, and race. | ||||||||
Cotignola et al. Journal of Negative Results in BioMedicine 2007 6:9 doi:10.1186/1477-5751-6-9 |
||||||||
